LAS VEGAS — A $100 million class action lawsuit filed against Astrola Pharmaceuticals could set a precedent for class action lawsuits, potentially opening the door for the largest class action ever filed in the United States.
The suit is being filed by a class of AstraMed customers who have been receiving AstraNets as a supplement for their acne, according to a report by the Las Vegas Review Journal.
The AstraNet is an oral spray that is currently marketed under the brand name AstraZena.
The Astra Zena brand is marketed under AstraPram, which is owned by Pfizer.
The lawsuit was filed by the class action law firm of the firm of Gartner LLP, which specializes in class action litigation.
In addition to the Astra-Zeneca lawsuit, the lawsuit claims AstraXa is a product of Astraprene, which the class has accused Pfizer of patent infringement and unfair competition.
According to the lawsuit, AstraZip is a generic version of Astramax, which Astra said it was “actively pursuing.”
Astra told the Las Vegas Review Journal it was pursuing an agreement with the class members.
AstraZeneca has denied the Astrapenes claims.
In a statement to The Wall St. Journal, the company said it does not have any pending patent applications relating to AstraClay and AstraLoft.
“Our AstraPad is a powerful, effective, long-lasting, and highly effective treatment that can be used with AstraMax and Astraplex.
We believe that AstraSnap is an effective, safe, and effective treatment for acne.
Our AstraSnaps have been shown to be more effective than AstraVals and Astraspray, and are available in more than 200 countries and in more markets than any other treatment on the market today,” the company added.